Healthcare / BiotechnologyShanghai
$22.51
-1.06 (-4.50%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-723.7M · quality 49.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$5.6B
P/E
45.0x
↑EV/EBITDA
19.3x
↑ROE
5.0%
↑Gross Margin
21.3%
↓Debt/Equity
0.78
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+26.4%
FCF CAGR
—
FCF margin
-18.6%
FCF / Net income
-4.02x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.86B · net income $132.4M · FCF $-532.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.86B | $2.86B | $2.18B | $1.94B | $1.42B |
| Net Income | $132.4M | $132.4M | $189.5M | $449.1M | $320.0M |
| EBITDA | $384.2M | $384.2M | $377.9M | $615.7M | $402.7M |
| EPS | 0.53 | 0.53 | 0.82 | 1.96 | 1.41 |
| Gross Margin | 21.3% | 21.3% | 24.9% | 40.5% | 38.7% |
| Operating Margin | 6.6% | 6.6% | 10.2% | 26.6% | 23.3% |
| Net Margin | 4.6% | 4.6% | 8.7% | 23.2% | 22.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.78 | 0.78 | 0.60 | 0.68 | 0.05 |
| Current Ratio | 1.21 | 1.21 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-532.2M | $-532.2M | $-723.7M | $-967.7M | $-98.9M |
| Returns | |||||
| ROE | 5.0% | 5.0% | 7.4% | 24.6% | 21.6% |
| Valuation | |||||
| P/E | 45.02 | 45.02 | 35.96 | 39.80 | 50.71 |
| EV/EBITDA | 19.26 | 19.26 | 21.01 | 30.48 | 40.13 |
| P/B | 2.12 | 2.12 | 2.66 | 9.78 | 10.96 |
| Growth & Yield | |||||
| Revenue Growth | 31.4% | 31.4% | 12.4% | 36.6% | — |
| EPS Growth | -35.4% | -35.4% | -58.2% | 39.3% | — |
| Dividend Yield | 0.7% | 0.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
55.6%
EPS terminal req.
$2.00
Spread vs growth
-91.0%
5Y implied EPS CAGR
35.5%
EPS terminal req.
$2.42
Spread vs growth
-70.8%
10Y implied EPS CAGR
22.1%
EPS terminal req.
$3.89
Spread vs growth
-57.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.8%
Start / end P/E
36.9x → 42.5x
EPS bridge
0.82 → 0.53
Residual
-5.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.